Literature DB >> 6879446

Sclerosing cholangitis: biliary reconstruction with Silastic transhepatic stents.

J L Cameron, B W Gayler, H F Herlong, W C Maddrey.   

Abstract

Because of multiple areas of stricturing and small fibrotic ducts, sclerosing cholangitis has generally not been amenable to direct reconstructive procedures. In reviewing the cholangiograms of 29 patients with sclerosing cholangitis, it became apparent that despite diffuse disease, the hepatic duct bifurcation was often (22 patients) the most severely narrowed area. Because of this finding it was decided to manage patients who have sclerosing cholangitis, persistent jaundice, and hepatic duct bifurcation narrowing with a direct surgical approach. In 11 patients the extrahepatic biliary tree including the bifurcation was resected and the right and left hepatic ducts were dilated. Bilateral 6 mm silicone rubber (Silastic) transhepatic biliary stents were inserted and bilateral hepaticojejunostomy was performed. Eight patients were men, three were women, and the mean age was 41.9 years. At the time of surgery the mean serum bilirubin concentration was 15.3 mg/dl (range 1 to 50 mg/dl). The disease had been present clinically for a mean duration of 3.6 years. There was one hospital death. Nine of the ten remaining patients have responded with a decrease in serum bilirubin concentration to a mean of 2.9 mg/dl. These nine patients have returned to normal activity. The tenth patient has done poorly and awaits liver transplantation. Follow-up ranges from 4 to 36 months (mean 18 months). The stents have been left in position permanently.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6879446

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Localized primary sclerosing cholangitis mimicking a cholecystectomy stricture relieved by an endoprosthesis.

Authors:  R Oren; E Goldin; N Harats; E Libson; D Shouval
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

2.  Orthotopic liver transplantation for primary sclerosing cholangitis.

Authors:  J W Marsh; S Iwatsuki; L Makowka; C O Esquivel; R D Gordon; S Todo; A Tzakis; C Miller; D Van Thiel; T E Starzl
Journal:  Ann Surg       Date:  1988-01       Impact factor: 12.969

3.  Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.

Authors:  J A Goss; C R Shackleton; D G Farmer; W S Arnaout; P Seu; J S Markowitz; P Martin; R J Stribling; L I Goldstein; R W Busuttil
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Balloon dilatation of biliary strictures through a choledochojejuno-cutaneous fistula.

Authors:  D G Hutson; E Russell; E Schiff; J J Levi; L Jeffers; R Zeppa
Journal:  Ann Surg       Date:  1984-06       Impact factor: 12.969

5.  Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation.

Authors:  A C Stieber; I R Marino; S Iwatsuki; T E Starzl
Journal:  Int Surg       Date:  1989 Jan-Mar

6.  Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis.

Authors:  J L Cameron; H A Pitt; M J Zinner; H F Herlong; S L Kaufman; J K Boitnott; J Coleman
Journal:  Ann Surg       Date:  1988-05       Impact factor: 12.969

7.  Improving biliary-enteric drainage in primary sclerosing cholangitis: experience with endoscopic methods.

Authors:  M Lombard; M Farrant; J Karani; D Westaby; R Williams
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

8.  Sclerosing cholangitis. Anatomical distribution of obstructive lesions.

Authors:  J L Cameron; B W Gayler; H Sanfey; F Milligan; S Kaufman; W C Maddrey; H F Herlong
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

9.  Change in hepatic function, hemodynamics, and morphology after liver transplant. Physiological effect of therapy.

Authors:  W J Millikan; J M Henderson; M T Stewart; W D Warren; J W Marsh; J R Galloway; H Jennings; S Kawasaki; T F Dodson; C A Perlino
Journal:  Ann Surg       Date:  1989-05       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.